Institute for Hepatology, National Clinical Research Center for Infectious Disease, Shenzhen Third People's Hospital, The Second Affiliated Hospital, School of Medicine, Southern University of Science and Technology, Shenzhen, 518112, Guangdong Province, China.
Guangdong Key Laboratory for Anti-Infection Drug Quality Evaluation, Shenzhen, 518112, Guangdong Province, China.
Virol J. 2022 May 28;19(1):96. doi: 10.1186/s12985-022-01827-w.
The SARS-CoV-2 nucleocapsid protein (NP) is an important indicator for the virus infection, highlighting the crucial role of NP-specific monoclonal antibodies (mAbs) used in multiple biochemical assays and clinical diagnosis for detecting the NP antigen. Here, we reported a pair of noncompeting human NP-specific mAbs, named P301-F7 and P301-H5, targeting two distinct linear epitopes on SARS-CoV-2 or SARS-CoV. We evaluated the application of P301-F7 in the analysis of enzyme linked immunosorbent assay, western blot, flow cytometry, immunofluorescence, and focus reduction neutralization test. We for the first time report a broad mAb effectively recognizing various live viruses of SARS-CoV-2 variants including Alpha, Beta, Delta, and Omicron, indicating a wide range of application prospects.
严重急性呼吸综合征冠状病毒 2 核衣壳蛋白（NP）是病毒感染的一个重要指标，突出了 NP 特异性单克隆抗体（mAbs）在多种生化分析和临床诊断中用于检测 NP 抗原的关键作用。在这里，我们报告了一对非竞争的人类 NP 特异性 mAbs，命名为 P301-F7 和 P301-H5，针对 SARS-CoV-2 或 SARS-CoV 上两个不同的线性表位。我们评估了 P301-F7 在酶联免疫吸附试验、western blot、流式细胞术、免疫荧光和蚀斑减少中和试验中的应用。我们首次报道了一种广谱 mAb 能够有效识别包括 Alpha、Beta、Delta 和 Omicron 在内的 SARS-CoV-2 变体的各种活病毒，表明其具有广泛的应用前景。
